Kinetic and mutagenic characterization of the chromosomally encoded Salmonella enterica AAC(6′)-Iy aminoglycoside N-acetyltransferase

被引:44
作者
Magnet, S
Lambert, T
Courvalin, P
Blanchard, JS
机构
[1] Inst Pasteur, Unite Agents Antibacteriens, F-75015 Paris, France
[2] Ctr Etud Pharmaceut, F-92296 Chatenay Malabry, France
关键词
D O I
10.1021/bi002736e
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The chromosomally encoded aminoglycoside N-acetyltransferase, AAC(6')-Iy, from Salmonella enterica confers resistance toward a number of aminoglycoside antibiotics. The structural gene was cloned and expressed and the purified enzyme existed in solution as a dimer of ca. 17 000 Da monomers. Acetyl-CoA was the preferred acyl donor, and most therapeutically important aminoglycosides were substrates for acetylation. Exceptions are those aminoglycosides that possess a 6'-hydroxyl substituent (e.g., lividomycin). Thus, the enzyme exhibited regioselective and exclusive acetyltransferase activity to 6'-amine-containing aminoglycosides. The enzyme exhibited Michaelis-Menten kinetics for some aminoglycoside substrates but "substrate activation" with others. Kinetic studies supported a random kinetic mechanism for the enzyme. The enzyme was inactivated by iodoacetamide in a biphasic manner, with half of the activity being lost rapidly and the other half more slowly. Tobramycin, but not acetyl-CoA, protected against inactivation. Each of the three cysteine residues (C70, C109, C145) in the wild-type enzyme were carboxamidomethylated by iodoacetamide. Cysteine 109 in AAC(6')-Iy is conserved in 12 AAC(6') enzyme sequences of the major class I subfamily. Surprisingly, mutation of this residue to alanine neither abolished activity nor altered the biphasic inactivation by iodoacetamide. The maximum velocity and V/K values for a number of aminoglycosides were elevated in this single mutant, and the kinetic behavior of substrates exhibiting linear vs nonlinear kinetics was reversed. Cysteine 70 in AAC(6')-Iy is either a cysteine or a threonine residue in all 12 AAC(6') enzymes of the major class I subfamily. The double mutant, C109A/C70A, was not inactivated by iodoacetamide. The double mutant exhibited large increases in the K-m values for both acetyl-CoA and aminoglycoside substrates, and all aminoglycoside substrates exhibited Michaelis-Menten kinetics. Solvent kinetic isotope effects on V/K were normal for the WT enzyme and inverse for the double mutant. We discuss a chemical mechanism and the likely rate-limiting steps for both the wild-type and mutant forms of the enzyme.
引用
收藏
页码:3700 / 3709
页数:10
相关论文
共 26 条
[1]   Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides [J].
Aires, JR ;
Köhler, T ;
Nikaido, H ;
Plésiat, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2624-2628
[2]  
Cleland W W, 1979, Methods Enzymol, V63, P103
[3]   PLASMID-MEDIATED RESISTANCE TO AMINOCYCLITOL ANTIBIOTICS IN GROUP-D STREPTOCOCCI [J].
COURVALIN, P ;
CARLIER, C ;
COLLATZ, E .
JOURNAL OF BACTERIOLOGY, 1980, 143 (02) :541-551
[4]  
DANG P, 1988, REV INFECT DIS, V10, P899
[5]   MECHANISM OF BACTERICIDAL ACTION OF AMINOGLYCOSIDES [J].
DAVIS, BD .
MICROBIOLOGICAL REVIEWS, 1987, 51 (03) :341-350
[6]  
HOOPER IR, 1982, HDB EXPT PHARM
[7]   Relationship between spontaneous aminoglycoside resistance in Escherichia coli and a decrease in oligopeptide binding protein [J].
Kashiwagi, K ;
Tsuhako, MH ;
Sakata, K ;
Saisho, T ;
Igarashi, A ;
da Costa, SOP ;
Igarashi, K .
JOURNAL OF BACTERIOLOGY, 1998, 180 (20) :5484-5488
[8]   Activation of the cryptic aac(6′)-Iy aminoglycoside resistance gene of Salmonella by a chromosomal deletion generating a transcriptional fusion [J].
Magnet, S ;
Courvalin, P ;
Lambert, T .
JOURNAL OF BACTERIOLOGY, 1999, 181 (21) :6650-6655
[9]  
MILLER GH, 1995, J CHEMOTHERAPY, V7, P31
[10]   Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei [J].
Moore, RA ;
DeShazer, D ;
Reckseidler, S ;
Weissman, A ;
Woods, DE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :465-470